Company / Capital Expenditures
Dexcom Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$363.5M
FY2025
5-year range
$199.0M / $389.2M
FY2021-FY2025
Trend
+1.3%
vs FY2024
Sector context
#31 of 151
Health Care
What the data says
Dexcom's capital expenditures of $364M is higher than 79% of companies in the Health Care sector (FY2025). Capital Expenditures has increased for 3 consecutive years, from $199M in FY2022 to $364M in FY2025.
Based on SEC 10-K filings.
$364M in FY2025 with a 5-year CAGR of +12.8%. Top quartile in the Health Care sector.
Improved from $237M to $364M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +22.2%
- 5-Year CAGR
- +12.8%
- 10-Year CAGR
- -
Sector benchmark
+33.8% above sector average
Key checks
Key Insights
- Dexcom's capital expenditures has grown for 3 consecutive years.
- 5-year CAGR of +12.8%, indicating consistent growth.
- In FY2025, capital expenditures increased 1.3% year-over-year.
- Ranks #31 out of 151 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
- Strong return on equity: 26.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $363.5M | +1.3% |
| FY2024 | $358.8M | +51.6% |
| FY2023 | $236.6M | +18.9% |
| FY2022 | $199.0M | -48.9% |
| FY2021 | $389.2M | +95.6% |
| FY2020 | $199.0M | +10.6% |
| FY2019 | $180.0M | +168.3% |
| FY2018 | $67.1M | +101.5% |
| FY2017 | $33.3M | +105.6% |
| FY2016 | $16.2M | +105.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026